Age: 51.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site mass, Vaccination site pain
Clinical narrative: Injection site: pain, palm-sized hard lump, very sensitive to movement and touch; Injection site: pain, palm-sized hard lump, very sensitive to movement and touch; Injection site: pain, palm-sized hard lump, very sensitive to movement and touch; Left arm: itching on forearm; Left neck: stiffness and a puffy/full feeling around lymph nodes on left side behind ear/jaw.; Left neck: stiffness and a puffy/full feeling around lymph nodes on left side behind ear/jaw.; General: joint and muscle pain, muscle weakness at hips, mild to moderate frontal headache, slightly elevated temperature (not a fever), but breath felt warm; General: joint and muscle pain, muscle weakness at hips, mild to moderate frontal headache, slightly elevated temperature (not a fever), but breath felt warm; General: joint and muscle pain, muscle weakness at hips, mild to moderate frontal headache, slightly elevated temperature (not a fever), but breath felt warm; General: joint and muscle pain, muscle weakness at hips, mild to moderate frontal headache, slightly elevated temperature (not a fever), but breath felt warm; General: joint and muscle pain, muscle weakness at hips, mild to moderate frontal headache, slightly elevated temperature (not a fever), but breath felt warm; General: joint and muscle pain, muscle weakness at hips, mild to moderate frontal headache, slightly elevated temperature (not a fever), but breath felt warm; This is a spontaneous report from a contactable consumer, the patient. A 51-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8737) via an unspecified route of administration in the left arm on 07Apr2021 at 02:30 (at the age of 51-years-old) as a single dose for COVID-19 immunisation. Medical history included psoriasis, psoriatic arthritis, lymphedema (1x) and recurrent ear infection. The patient previously took Wellbutrin and experienced drug allergy. Concomitant medications taken within two weeks prior to vaccination included apremilast 30 milligram /2x a day (OTEZLA) and sertraline 50 milligram /1x a day (MANUFACTURER UNKNOWN) both from unknown date for unknown indication. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 08Apr2021 at 01:45, the patient experienced injection site pain, palm-sized hard lump, very sensitive to movement and touch. The patients left arm was itching on forearm and she experienced left neck stiffness and a puffy/full feeling around lymph nodes on left side behind ear/jaw. In general the patient had joint and muscle pain, muscle weakness at hips, mild to moderate frontal headache, slightly elevated temperature (not a fever), but her breath felt warm. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the events. The clinical outcome of the events injection site pain, palm-sized hard lump, very sensitive to movement and touch, left arm was itching on forearm, left neck stiffness and a puffy/full feeling around lymph nodes on left side behind ear/jaw, joint and muscle pain, muscle weakness at hips, mild to moderate frontal headache, slightly elevated temperature (not a fever), but breath felt warm was resolving at the time of this report.  No follow-up attempts are needed. No further information is expected.